AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,448 | +46.1% | 941,433 | +50.9% | 0.11% | +70.3% |
| Q2 2023 | $7,836 | +353.5% | 623,853 | +300.3% | 0.06% | +357.1% |
| Q1 2023 | $1,728 | +22.2% | 155,835 | +34.6% | 0.01% | -33.3% |
| Q4 2022 | $1,414 | -100.0% | 115,791 | -60.5% | 0.02% | -47.5% |
| Q3 2022 | $3,059,000 | +120.4% | 292,980 | +126.7% | 0.04% | +135.3% |
| Q2 2022 | $1,388,000 | +478.3% | 129,234 | +522.6% | 0.02% | +750.0% |
| Q4 2021 | $240,000 | -87.3% | 20,758 | -89.5% | 0.00% | -92.0% |
| Q3 2021 | $1,889,000 | +121.7% | 197,771 | +123.7% | 0.02% | +177.8% |
| Q2 2021 | $852,000 | -5.5% | 88,395 | -3.2% | 0.01% | -30.8% |
| Q1 2021 | $902,000 | -51.9% | 91,337 | +12.5% | 0.01% | -27.8% |
| Q4 2020 | $1,875,000 | +24.7% | 81,190 | -23.8% | 0.02% | -40.0% |
| Q3 2020 | $1,504,000 | +232.7% | 106,516 | +129.3% | 0.03% | +275.0% |
| Q4 2019 | $452,000 | +148.4% | 46,457 | +104.7% | 0.01% | +33.3% |
| Q3 2019 | $182,000 | – | 22,700 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |